Table 5. Patient-derived utility coefficients: overall and according to treatment.

Health state	N a	SHE	TTO=1−(1−SHE)1.6
Mean SHE scores within patients with SD-CT (months: 1, 2, 3, 4, 5, 6) or DI-EC (months 2, 3)
TOX
Total sample	284	0.60	0.77
SD-CT	149	0.60	0.77
DI-EC	135	0.57	0.74
Mean SHE scores within patients reporting grade 3 or higher toxicity with SD-CT (months: 1, 2, 3, 4, 5, 6) or DI-EC (months 2, 3)
TOX
Total sample	96	0.53	0.70
SD-CT	27	0.51	0.68
DI-EC	69	0.55	0.72
TWiST
Total sample	292	0.78	0.91
SD-CT	140	0.80	0.92
DI-EC	152	0.77	0.90
REL
Total sample	85	0.60	0.77
SD-CT	51	0.55	0.72
DI-EC	34	0.64	0.80

Abbreviations: DI-EC=dose-intensive epirubicin cyclophosphamide; SD-CT=standard dose chemotherapy (ACx4-CMFx3); SHE=subjective health evaluation; TTO=time trade-off.

^aSample size reflects those patients who experienced that health state and who responded to the SHE question at least once during that health state.